ALUMIS INC
ALMSNASDAQTrading Snapshot
- Day Range
- $25.70 – $26.20
- 52-Week Range
- $3.76 – $31.35
- Volume
- $2.57B
- Avg Volume
- $3.36B
- Shares Outstanding
- 123.4M
- Next Earnings
- Oct 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $24M
- Last Q Revenue
- $2M
- P/E Ratio
- -13.6
- P/S Ratio
- 380.3x
- EPS (TTM)
- $-1.90
- Dividend Yield
- 0.00%
Why Investors Own ALMS
- ✓High-growth profile — revenue up +33.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 72% gross margin and 29% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ALUMIS INC
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Alumis Psoriasis Treatment Shows Leading Skin Clearance Rates
Alumis releases long-term data for psoriasis drug envudeucitinib, boasting top skin clearance rates ahead of a Q4 FDA filing with FDA.
Alumis Reports Topline Results From Ongoing ONWARD3 Long-Term Extension Study Showing 54% Of Patients Reached Complete Skin Clearance After 48 Weeks Of Continuous Envudeucitinib Treatment
– Favorable long-term safety and tolerability profile remained consistent with previously reported data –– On track to submit a New Drug Application to FDA in 4Q 2026 –SOUTH SAN FRANCISCO, Calif., Aug. 10, 2026 (GLOBE
HC Wainwright & Co. Reiterates Neutral on Alumis, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Alumis (NASDAQ:ALMS) with a Neutral and maintains $25 price target.